Speaker(s):

Nasim Adimi, MSHS, MS, PA-C, RD; Clinical Practice Liason, Madrigal Pharmaceuticals

Nasim, Clinical Practice Liaison, Madigral - Discloses that she works in the medical affairs department of Madrigal Pharmaceutical, as a Clinical Practice Liaison. Otherwise nothing to disclose. 

Moderator(s): 

Lorella Thomas, CRNP, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the spectrum, nomenclature, and natural history of MASH within the broader context of MASLD.
• Explain the pathophysiology of MASH, including key metabolic drivers and the role of THR-β signaling in disease progression.
• Apply clinical knowledge to practice by identifying risk factors, assessing disease burden, and utilizing appropriate diagnostic tools and management strategies for patients with MASH.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Karla Leschinsky, PA-C; Briget Stem, RN; Alyssa Bertram, PharmD and Lorella Thomas, CRNP have no identified disclosures. 

Sara Gaines, PharmD and Daniel Longyhore, PharmD, MS, EdD

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None